Patent ID: 9440971
Filing Date: 2016-09-13
CPC Classification: A61K,A61P,C07D

Claim Text:
1. A crystalline form of Vemurafenib hydrochloride salt, designated as Form II, characterized by one or more of the following: a powder X-ray diffraction pattern having peaks at 5.0, 9.9, 15.7, 19.8 and 22.1 degrees two theta±0.2 degrees two theta; a powder X-ray diffraction pattern substantially as depicted in a solid-state 13C NMR spectrum having characteristic peaks at 51.0, 114.5, 132.3, 138.0 and 139.5 ppm, ±0.2 ppm; a solid state 13C NMR spectrum having chemical shift differences between said characteristic peaks and a peak at 120.9 ppm±0.2 ppm of −69.9, −6.4, 11.4, 17.1 and 18.6±0.1 ppm, respectively; a solid state 13C NMR spectrum substantially as shown in or any combination of these data.